About Us

Improved Pharma - is a consulting firm specializing in early-phase drug development, accelerating proof of concept in a cost-effective manner.  Improved Pharma combines one or more of the services outlined below to accelerate proof of concept while at the same time reducing risk and achieving quality by design. Improved Pharma offers the following services through its subcontractors.

  • Solid state chemistry including solid forms, solid form screening, polymorphism, salts, hydrates, cocrystals, amorphous forms, stability
  • API synthesis,
  • Formulation and manufacturability
  • Clinical supplies manufacture
  • Preclinical studies
  • Regulatory support and clinical trial support and design
  • Intellectual property

Strategy: Improved Pharma integrates services from highly reputable contractors/partners/university laboratories throughout the world. Improved Pharma thus serves as a single point of contact for a vast network of external experts.  This provides access to skills far beyond that of an individual CRO. Improved Pharma believes that by focusing on solid state chemistry along with effective planning and implementation leads to a fast, cost-effective drug development program.  Improved Pharma also has expertise in finding creative solutions to a wide range of drug development problems.   From its offices in West Lafayette, Indiana, it is well positioned to interact with contractors/partners.  The partners of Improved Pharma contribute their expertise and capability to the problem at hand.  Improved Pharma integrates these suppliers and their expertise in a highly efficient, economical way. 

Information Management: Improved Pharma integrates data from each area/subcontractor using templates.  These templates are then combined into the final IND, regulatory submission, or final report.  Improved Pharma uses an in-house project management/data-base system named FPOC to provide its customers instantaneous feedback on the progress of their project. This allows fast, informed decision making. FPOC also contains a preformulation/stability prediction module that facilitates decision making in cases where development is difficult due to stability problems.

Stephen R. Byrn, CSO

Stephen R. Byrn, Ph. D. is Charles B. Jordan Professor of Medicinal Chemistry in the Department of Industrial and Physical Pharmacy, Purdue University, West Lafayette, Indiana.  Dr. Byrn authored the first book addressing the field of solid state chemistry of drugs in 1982 (second edition, 2000). He continues to be involved in educating scientists in solid state chemistry, industrial & physical pharmacy, methods of analysis, and regulatory science.Dr. Byrn has served as chair of the Pharmaceutical Sciences Advisory Committee to the FDA and chaired several USP committees. Dr. Byrn founded Purdue’s graduate programs in regulatory and quality compliance which includes several courses in CMC and formulation/quality by design.  Dr. Byrn also founded and directed Purdue's Center for AIDS Research.  Dr. Byrn co-founded SSCI, Inc. (Solid State Chemical Information) a cGMP research and information company specializing in crystallization, analysis, and regulatory issues.  SSCI, Inc. is now owned by Aptuit.  Dr. Byrn is also a technical founder of Andara now owned by Neurometrix, Inc. Andara develops drugs and devices for spinal cord injuries and nerve disorders.

George Zografi, Senior Consultant

George Zografi, Ph.D. is the Edward Kremers Professor Emeritus of Pharmaceutical Sciences, School of Pharmacy at the University of Wisconsin, Madison.  He received his B.S. in Pharmacy from Columbia University in 1956 and Ph.D. in Pharmaceutical Chemistry from the University of Michigan in 1960.  In 1972, after serving on the faculties of Columbia University and the University of Michigan, he joined the faculty of the University of Wisconsin.  From 1975-1980 he served as Dean of the School of Pharmacy. Dr. Zografi’s research interests have been focused in two areas: the properties of solids in the in the amorphous state and the surface chemistry of lipids, polymers and proteins in monolayer and bilayer systems, as they both relate to various aspects of the drug development process.  He was the recipient of the APhA Ebert Prize in 1984 and 2001, the AAPS Dale E. Wurster Award for Pharmaceutics in 1990, the AAPS Distinguished Scientist Award in 1995 and the AACP Volwiler Research Achievement Award in 1996.  In 1989, he was elected to the Institute of Medicine of the National Academy of Sciences.

Contact us for more information about our consulting services or our fast track program.

Short Course Updates

Get notifications about upcoming short courses.

Slide 1

Powerful methods of analysis including IVIVC

Slide 2

Informatics system to insure quality documents

Improved Pharma - We make drugs faster...

Strong IP assigned to client

Improved Pharma - We make drugs faster...

Quality by Design for formulations

Improved Pharma - We make drugs faster...

Rapid assessment of the risk of stability problems

Improved Pharma - We make drugs faster...

Fast screening for the right solid form....